Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation with Insulin Resistance, Inflammation, and Liver Histology
Background and Aim Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effe...
Saved in:
Published in | Journal of investigative medicine Vol. 63; no. 7; pp. 871 - 877 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Los Angeles, CA
SAGE Publications
01.10.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background and Aim
Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effects of insulin resistance and inflammatory biomarkers on asymmetric dimethylarginine (ADMA) levels, a predictor of CVD. We also investigated relationship between these markers and histological findings in patients with NAFLD.
Patients and Methods
Plasma ADMA, high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and homeostasis model assessment of insulin resistance (HOMA-IR) were measured in 70 patients with histologically verified NAFLD (53 with nonalcoholic steatohepatitis [NASH], 17 with non-NASH) and 12 controls.
Results
The HOMA-IR (5.3 [3.9] vs 1.9 [1], P < 0.001), hs-CRP (5.6 [4.2] vs 2.2 [2.3] mg/L, P < 0.001), ADMA (0.81 [0.25] vs 0.48 [0.24] μmol/L, P = 0.005), and IL-6 (4.1 [1.2] vs 1.0 [0.4] pg/mL, P < 0.001) levels were all found higher in the NAFLD group than the control group. The ADMA levels were significantly higher in patients with NAFLD independent from HOMA-IR and body composition (P = 0.02). The IL-6 and HOMA-IR levels of the NASH group were found significantly higher than those of the non-NASH group. The only determinant significantly correlated to ADMA was HOMA-IR.
Conclusions
Our data suggested that although ADMA levels are independently higher in NAFLD, the only determinant correlated to ADMA is HOMA-IR and not inflammatory biomarkers (hs-CRP, IL-6) or presence/absence of NASH. |
---|---|
AbstractList | Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effects of insulin resistance and inflammatory biomarkers on asymmetric dimethylarginine (ADMA) levels, a predictor of CVD. We also investigated relationship between these markers and histological findings in patients with NAFLD.
Plasma ADMA, high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and homeostasis model assessment of insulin resistance (HOMA-IR) were measured in 70 patients with histologically verified NAFLD (53 with nonalcoholic steatohepatitis [NASH], 17 with non-NASH) and 12 controls.
The HOMA-IR (5.3 [3.9] vs 1.9 [1], P < 0.001), hs-CRP (5.6 [4.2] vs 2.2 [2.3] mg/L, P < 0.001), ADMA (0.81 [0.25] vs 0.48 [0.24] μmol/L, P = 0.005), and IL-6 (4.1 [1.2] vs 1.0 [0.4] pg/mL, P < 0.001) levels were all found higher in the NAFLD group than the control group. The ADMA levels were significantly higher in patients with NAFLD independent from HOMA-IR and body composition (P = 0.02). The IL-6 and HOMA-IR levels of the NASH group were found significantly higher than those of the non-NASH group. The only determinant significantly correlated to ADMA was HOMA-IR.
Our data suggested that although ADMA levels are independently higher in NAFLD, the only determinant correlated to ADMA is HOMA-IR and not inflammatory biomarkers (hs-CRP, IL-6) or presence/absence of NASH. Background and Aim Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effects of insulin resistance and inflammatory biomarkers on asymmetric dimethylarginine (ADMA) levels, a predictor of CVD. We also investigated relationship between these markers and histological findings in patients with NAFLD. Patients and Methods Plasma ADMA, high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and homeostasis model assessment of insulin resistance (HOMA-IR) were measured in 70 patients with histologically verified NAFLD (53 with nonalcoholic steatohepatitis [NASH], 17 with non-NASH) and 12 controls. Results The HOMA-IR (5.3 [3.9] vs 1.9 [1], P < 0.001), hs-CRP (5.6 [4.2] vs 2.2 [2.3] mg/L, P < 0.001), ADMA (0.81 [0.25] vs 0.48 [0.24] μmol/L, P = 0.005), and IL-6 (4.1 [1.2] vs 1.0 [0.4] pg/mL, P < 0.001) levels were all found higher in the NAFLD group than the control group. The ADMA levels were significantly higher in patients with NAFLD independent from HOMA-IR and body composition ( P = 0.02). The IL-6 and HOMA-IR levels of the NASH group were found significantly higher than those of the non-NASH group. The only determinant significantly correlated to ADMA was HOMA-IR. Conclusions Our data suggested that although ADMA levels are independently higher in NAFLD, the only determinant correlated to ADMA is HOMA-IR and not inflammatory biomarkers (hs-CRP, IL-6) or presence/absence of NASH. BACKGROUND AND AIMCardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effects of insulin resistance and inflammatory biomarkers on asymmetric dimethylarginine (ADMA) levels, a predictor of CVD. We also investigated relationship between these markers and histological findings in patients with NAFLD.PATIENTS AND METHODSPlasma ADMA, high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and homeostasis model assessment of insulin resistance (HOMA-IR) were measured in 70 patients with histologically verified NAFLD (53 with nonalcoholic steatohepatitis [NASH], 17 with non-NASH) and 12 controls.RESULTSThe HOMA-IR (5.3 [3.9] vs 1.9 [1], P < 0.001), hs-CRP (5.6 [4.2] vs 2.2 [2.3] mg/L, P < 0.001), ADMA (0.81 [0.25] vs 0.48 [0.24] μmol/L, P = 0.005), and IL-6 (4.1 [1.2] vs 1.0 [0.4] pg/mL, P < 0.001) levels were all found higher in the NAFLD group than the control group. The ADMA levels were significantly higher in patients with NAFLD independent from HOMA-IR and body composition (P = 0.02). The IL-6 and HOMA-IR levels of the NASH group were found significantly higher than those of the non-NASH group. The only determinant significantly correlated to ADMA was HOMA-IR.CONCLUSIONSOur data suggested that although ADMA levels are independently higher in NAFLD, the only determinant correlated to ADMA is HOMA-IR and not inflammatory biomarkers (hs-CRP, IL-6) or presence/absence of NASH. |
Author | Alkim, Canan Koksal, Ali Riza Neijmann, Sebnem Tekin Ozgon, Gulay Ozguven, Muveddet Banu Yilmaz Ergun, Meltem Boga, Salih Alkim, Huseyin Bayram, Mehmet |
Author_xml | – sequence: 1 givenname: Salih surname: Boga fullname: Boga, Salih organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey – sequence: 2 givenname: Huseyin surname: Alkim fullname: Alkim, Huseyin organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey – sequence: 3 givenname: Ali Riza surname: Koksal fullname: Koksal, Ali Riza organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey – sequence: 4 givenname: Mehmet surname: Bayram fullname: Bayram, Mehmet organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey – sequence: 5 givenname: Muveddet Banu Yilmaz surname: Ozguven fullname: Ozguven, Muveddet Banu Yilmaz organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey – sequence: 6 givenname: Meltem surname: Ergun fullname: Ergun, Meltem organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey – sequence: 7 givenname: Sebnem Tekin surname: Neijmann fullname: Neijmann, Sebnem Tekin organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey – sequence: 8 givenname: Gulay surname: Ozgon fullname: Ozgon, Gulay organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey – sequence: 9 givenname: Canan surname: Alkim fullname: Alkim, Canan organization: Nesiller Genetics Diagnostic Lab, Istanbul, Turkey |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26244718$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kctu1TAQhi1URC_wBgh5yaIpdi5Owq4qlB50uKiCdTRxxue4cuziSYryNH3VupwDQiyYzYys7_9Hnv-YHfjgkbGXUpxJ0dZvPq4-nYm_Ky_EE3Yka9FkTa7qgzSLRmZV1bSH7JjoJiGqavNn7DBXeVnWsjli9yuvIwLhwL86oBH4Gu_QEQ-Gn9MyjjhFq_k7m4bt4iBurLceufX8c_DgdNgGl4BLmKaFr-0dxgTTo-Nbfo0OJhs8_2mnLV95ml3SXSNZmsBrPE1vxsE4_qJOOfhhb3GViODCZnnOnhpwhC_2_YR9v3z_7eIqW3_5sLo4X2e6KNspUzD0WNRGiUb0mD5agpGqMWWle0gXyBHyqlGy70tTFGhQIepelqXu80EZLE7Y653vbQw_ZqSpGy1pdA48hpk6WUvVFnXVioSWO1THQBTRdLfRjhCXToruMZouRdP9G02SvdpvmPsRhz-i31kkQO4Agg12N2GO6b70f9MH9KqdCQ |
CitedBy_id | crossref_primary_10_3390_antiox11050880 crossref_primary_10_1007_s13312_017_1143_x crossref_primary_10_1016_j_apsb_2023_05_020 crossref_primary_10_1039_C9RA00669A crossref_primary_10_1016_j_cld_2017_08_009 crossref_primary_10_1186_s12967_020_02637_w crossref_primary_10_3390_ijms21249646 crossref_primary_10_1089_ars_2016_6742 crossref_primary_10_1093_jn_nxaa032 crossref_primary_10_3390_medicina56110622 crossref_primary_10_1002_jcb_28021 |
Cites_doi | 10.1016/j.jchromb.2006.09.023 10.1016/S0002-9149(01)02063-X 10.1177/1358836X0501000106 10.1016/j.jhep.2008.06.018 10.1016/j.jhep.2004.03.016 10.1161/01.CIR.98.18.1842 10.1111/j.1365-2362.2007.01814.x 10.1016/j.cgh.2008.11.005 10.2215/CJN.11291210 10.1681/ASN.V103594 10.1111/j.1572-0241.2007.01774.x 10.1016/S0140-6736(01)07217-8 10.3109/00365520903443852 10.2337/dc06-9913 10.1042/cs1000161 10.1016/j.numecd.2010.10.003 10.1097/00005344-199904000-00020 10.1016/j.atherosclerosis.2009.10.034 10.1001/jama.287.11.1420 10.1161/01.CIR.99.24.3092 10.1177/1358863X10364552 10.1016/S0008-6363(03)00500-5 10.1177/0148607108321702 10.1097/00005344-199204002-00018 10.1016/j.ijcard.2006.11.058 10.1161/01.CIR.0000111245.75752.C6 10.1042/CS20030285 10.1007/s12020-012-9712-1 10.1016/S0735-1097(01)01318-3 10.1159/000336669 10.1016/0140-6736(92)90865-Z 10.1210/jc.2006-2643 10.1002/hep.20701 10.1007/s00125-002-0975-6 10.1016/j.metabol.2010.07.027 10.1161/01.RES.0000181286.44222.61 |
ContentType | Journal Article |
Copyright | 2015 American Federation for Medical Research |
Copyright_xml | – notice: 2015 American Federation for Medical Research |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1097/JIM.0000000000000230 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1708-8267 |
EndPage | 877 |
ExternalDocumentID | 10_1097_JIM_0000000000000230 26244718 10.1097_JIM.0000000000000230 |
Genre | Journal Article |
GroupedDBID | --- .55 .GJ .Z2 0-V 0R~ 1CY 36B 3O- 3V. 53G 5GY 5VS 7X7 88E 8FI 8FJ 8G5 AAEWN AAKAS AATAA AAWTL AAYAA ABBUW ABJNI ABPNF ABRHV ABUWG ABVAJ ABWEH ABZAD ACDDN ACGFS ACOXC ACUIR ACWDW ACWRI ADBBV ADBIZ ADMRH ADZCM AEAXR AENEX AEXNY AFKRA AFTRI AGKLV AHMBA AHQMW AIZYK AJYBZ ALIPV ALKDR ALMA_UNASSIGNED_HOLDINGS ALSLI ALTZF ARALO ARTOV AZQEC BENPR BGRYB BKSCU BOMFT BPACV BPHCQ BVXVI C45 CCPQU CS3 DU5 DWQXO E.X EBS EJD EMB EX3 F5P FHBDP FL- FYUFA GNUQQ GUQSH HAJ HMCUK HZ~ IN~ J8X KD2 M0O M1P M2O NTWIH O9- OVD P2P PQQKQ PROAC PSQYO RHF RHI RMJ S4S SFC SJN SV3 TEORI TWG UKHRP V2I W3M WH7 WOQ WOW X7M ZXP ABKLS ABKRM ACARO ALKWR CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c349t-6adbe37f6080be0024af168f45cba5582ea25861bb4f33efe6eecb144cb2d6fe3 |
ISSN | 1081-5589 |
IngestDate | Fri Aug 16 23:30:23 EDT 2024 Fri Aug 23 03:45:11 EDT 2024 Sat Sep 28 08:03:46 EDT 2024 Tue Jul 16 20:34:19 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | HOMA-IR NAFLD hs-CRP asymmetric dimethylarginine IL-6 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c349t-6adbe37f6080be0024af168f45cba5582ea25861bb4f33efe6eecb144cb2d6fe3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 26244718 |
PQID | 1716937590 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1716937590 crossref_primary_10_1097_JIM_0000000000000230 pubmed_primary_26244718 sage_journals_10_1097_JIM_0000000000000230 |
PublicationCentury | 2000 |
PublicationDate | 20151000 2015-Oct 2015-10-00 20151001 |
PublicationDateYYYYMMDD | 2015-10-01 |
PublicationDate_xml | – month: 10 year: 2015 text: 20151000 |
PublicationDecade | 2010 |
PublicationPlace | Los Angeles, CA |
PublicationPlace_xml | – name: Los Angeles, CA – name: England |
PublicationTitle | Journal of investigative medicine |
PublicationTitleAlternate | J Investig Med |
PublicationYear | 2015 |
Publisher | SAGE Publications |
Publisher_xml | – name: SAGE Publications |
References | Vizzutti, Romanelli, Arena 2007; 37 Cavusoglu, Ruwende, Chopra 2010; 210 Zoccali, Bode-Böger, Mallamaci 2001; 358 Ong, Pitts, Younossi 2008; 49 Milic, Stimac 2012; 30 Horowitz, Heresztyn 2007; 851 Altinova, Arslan, Sepici-Dincel 2007; 92 Vallance, Leone, Calver 1992; 20 Colak, Senates, Yesil 2013; 43 Kielstein, Böger, Bode-Böger 1999; 10 Garcia, Perez, Maas 2007; 122 Sydow, Mondon, Cooke 2005; 10 Tripepi, Mattace Raso, Sijbrands 2011; 6 Siervo, Corander, Stranges 2011; 21 Schnabel, Blankenberg, Lubos 2005; 97 Abbasi, Asagmi, Cooke 2001; 88 Böger, Lentz, Bode-Böger 2001; 100 Lundman, Eriksson, Stühlinger 2001; 38 Kleiner, Brunt, Van Natta 2005; 41 Rafiq, Bai, Fang 2009; 7 Tsikas, Rode, Becker 2003; 38 Vallance, Leone, Calver 1992; 339 Wilson, Shin, Weatherby 2010; 15 Kasumov, Edmison, Dasarathy 2011; 60 Wieckowska, Papouchado, Li 2008; 103 Stuhlinger, Abbasi, Chu 2002; 2877 Grundy, Brewer, Cleeman 2004; 109 Ito, Tsao, Adimoolam 1999; 99 Videla, Rodrigo, Orellana 2004; 106 Böger 2003; 59 2006; 29 Surdacki, Nowicki, Sandmann 1999; 33 Lluch, Torondel, Medina 2004; 41 Boger, Bode-Boger, Szuba 1998; 98 Chan, Chan 2002; 45 Richir, Bouwman, Teerlink 2008; 32 Onat, Hergenç, Can 2008; 36 Kukla, Zwirska-Korczala, Hartleb 2010; 45 bibr12-JIM.0000000000000230 bibr24-JIM.0000000000000230 bibr29-JIM.0000000000000230 Onat A (bibr32-JIM.0000000000000230) 2008; 36 bibr7-JIM.0000000000000230 bibr31-JIM.0000000000000230 bibr33-JIM.0000000000000230 bibr38-JIM.0000000000000230 bibr26-JIM.0000000000000230 bibr19-JIM.0000000000000230 bibr34-JIM.0000000000000230 bibr22-JIM.0000000000000230 bibr27-JIM.0000000000000230 bibr4-JIM.0000000000000230 bibr15-JIM.0000000000000230 bibr10-JIM.0000000000000230 Tsikas D (bibr13-JIM.0000000000000230) 2003; 38 bibr2-JIM.0000000000000230 bibr17-JIM.0000000000000230 bibr36-JIM.0000000000000230 bibr9-JIM.0000000000000230 bibr3-JIM.0000000000000230 bibr8-JIM.0000000000000230 bibr37-JIM.0000000000000230 bibr28-JIM.0000000000000230 bibr25-JIM.0000000000000230 bibr20-JIM.0000000000000230 bibr6-JIM.0000000000000230 bibr5-JIM.0000000000000230 bibr14-JIM.0000000000000230 bibr1-JIM.0000000000000230 bibr30-JIM.0000000000000230 bibr21-JIM.0000000000000230 bibr23-JIM.0000000000000230 bibr18-JIM.0000000000000230 bibr11-JIM.0000000000000230 bibr35-JIM.0000000000000230 bibr16-JIM.0000000000000230 |
References_xml | – volume: 60 start-page: 776 issue: 6 year: 2011 end-page: 781 article-title: Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease publication-title: Metabolism contributor: fullname: Dasarathy – volume: 10 year: 2005 article-title: Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA publication-title: Vasc Med contributor: fullname: Cooke – volume: 38 start-page: 111 issue: 1 year: 2001 end-page: 116 article-title: Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine publication-title: J Am Coll Cardiol contributor: fullname: Stühlinger – volume: 32 start-page: 613 issue: 6 year: 2008 end-page: 621 article-title: The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function publication-title: JPEN J Parenter Enteral Nutr contributor: fullname: Teerlink – volume: 29 start-page: 1955 issue: 8 year: 2006 end-page: 1962 article-title: ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control publication-title: Diabetes Care – volume: 21 start-page: 1 issue: 1 year: 2011 end-page: 10 article-title: Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of asymmetric dimethylarginine (ADMA) publication-title: Nutr Metab Cardiovasc Dis contributor: fullname: Stranges – volume: 109 start-page: 433 issue: 3 year: 2004 end-page: 438 article-title: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition publication-title: Circulation contributor: fullname: Cleeman – volume: 7 start-page: 234 issue: 2 year: 2009 end-page: 238 article-title: Long-term follow-up of patients with nonalcoholic fatty liver publication-title: Clin Gastroenterol Hepatol contributor: fullname: Fang – volume: 122 start-page: 176 issue: 2 year: 2007 end-page: 178 article-title: Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome publication-title: Int J Cardiol contributor: fullname: Maas – volume: 20 year: 1992 article-title: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis publication-title: J Cardiovasc Pharmacol contributor: fullname: Calver – volume: 10 start-page: 594 issue: 3 year: 1999 end-page: 600 article-title: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease publication-title: J Am Soc Nephrol contributor: fullname: Bode-Böger – volume: 2877 start-page: 1420 issue: 11 year: 2002 end-page: 1426 article-title: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor publication-title: JAMA contributor: fullname: Chu – volume: 36 start-page: 7 issue: 1 year: 2008 end-page: 13 article-title: Serum asymmetric dimethylarginine levels among Turks: association with metabolic syndrome in women and tendency to decrease in smokers publication-title: Turk Kardiyol Dern Ars contributor: fullname: Can – volume: 30 start-page: 158 issue: 2 year: 2012 end-page: 162 article-title: Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment publication-title: Dig Dis contributor: fullname: Stimac – volume: 851 start-page: 42 issue: 1–2 year: 2007 end-page: 50 article-title: An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations publication-title: J Chromatogr B Analyt Technol Biomed Life Sci contributor: fullname: Heresztyn – volume: 15 start-page: 267 issue: 4 year: 2010 end-page: 274 article-title: Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease publication-title: Vasc Med contributor: fullname: Weatherby – volume: 38 start-page: 1063 issue: 4 year: 2003 end-page: 1064 article-title: Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease publication-title: Hepatology contributor: fullname: Becker – volume: 37 start-page: 509 issue: 6 year: 2007 end-page: 515 article-title: ADMA correlates with portal pressure in patients with compensated cirrhosis publication-title: Eur J Clin Invest contributor: fullname: Arena – volume: 59 start-page: 824 issue: 4 year: 2003 end-page: 833 article-title: The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor publication-title: Cardiovasc Res contributor: fullname: Böger – volume: 43 start-page: 100 issue: 1 year: 2013 end-page: 107 article-title: Assessment of endothelial function in patients with nonalcoholic fatty liver disease publication-title: Endocrine contributor: fullname: Yesil – volume: 98 start-page: 1842 year: 1998 end-page: 1847 article-title: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia publication-title: Circulation contributor: fullname: Szuba – volume: 41 start-page: 1313 issue: 6 year: 2005 end-page: 1321 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology contributor: fullname: Van Natta – volume: 88 start-page: 1201 issue: 10 year: 2001 end-page: 1203 article-title: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus publication-title: Am J Cardiol contributor: fullname: Cooke – volume: 103 year: 2008 article-title: Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis publication-title: Am J Gastroenterol contributor: fullname: Li – volume: 358 start-page: 2113 issue: 9299 year: 2001 end-page: 2117 article-title: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study publication-title: Lancet contributor: fullname: Mallamaci – volume: 106 start-page: 261 issue: 3 year: 2004 end-page: 268 article-title: Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients publication-title: Clin Sci (Lond) contributor: fullname: Orellana – volume: 210 start-page: 226 issue: 1 year: 2010 end-page: 231 article-title: Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography publication-title: Atherosclerosis contributor: fullname: Chopra – volume: 45 start-page: 1609 issue: 12 year: 2002 end-page: 1616 article-title: Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? publication-title: Diabetologia contributor: fullname: Chan – volume: 6 start-page: 1714 issue: 7 year: 2011 end-page: 1721 article-title: Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients publication-title: Clin J Am Soc Nephrol contributor: fullname: Sijbrands – volume: 92 start-page: 1881 issue: 5 year: 2007 end-page: 1885 article-title: Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations publication-title: J Clin Endocrinol Metab contributor: fullname: Sepici-Dincel – volume: 45 start-page: 235 issue: 2 year: 2010 end-page: 242 article-title: Serum chemerin and vaspin in non-alcoholic fatty liver disease publication-title: Scand J Gastroenterol contributor: fullname: Hartleb – volume: 49 start-page: 608 issue: 4 year: 2008 end-page: 612 article-title: Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease publication-title: J Hepatol contributor: fullname: Younossi – volume: 100 start-page: 161 issue: 2 year: 2001 end-page: 167 article-title: Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans publication-title: Clin Sci (Lond) contributor: fullname: Bode-Böger – volume: 99 start-page: 3092 issue: 24 year: 1999 end-page: 3095 article-title: Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase publication-title: Circulation contributor: fullname: Adimoolam – volume: 41 start-page: 55 issue: 1 year: 2004 end-page: 59 article-title: Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis publication-title: J Hepatol contributor: fullname: Medina – volume: 339 start-page: 572 issue: 8793 year: 1992 end-page: 575 article-title: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure publication-title: Lancet contributor: fullname: Calver – volume: 97 start-page: e53 issue: 5 year: 2005 end-page: e59 article-title: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study publication-title: Circ Res contributor: fullname: Lubos – volume: 33 start-page: 652 issue: 4 year: 1999 end-page: 658 article-title: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension publication-title: J Cardiovasc Pharmacol contributor: fullname: Sandmann – ident: bibr7-JIM.0000000000000230 doi: 10.1016/j.jchromb.2006.09.023 – ident: bibr14-JIM.0000000000000230 doi: 10.1016/S0002-9149(01)02063-X – volume: 36 start-page: 7 issue: 1 year: 2008 ident: bibr32-JIM.0000000000000230 publication-title: Turk Kardiyol Dern Ars contributor: fullname: Onat A – ident: bibr11-JIM.0000000000000230 doi: 10.1177/1358836X0501000106 – ident: bibr3-JIM.0000000000000230 doi: 10.1016/j.jhep.2008.06.018 – ident: bibr27-JIM.0000000000000230 doi: 10.1016/j.jhep.2004.03.016 – ident: bibr6-JIM.0000000000000230 doi: 10.1161/01.CIR.98.18.1842 – ident: bibr28-JIM.0000000000000230 doi: 10.1111/j.1365-2362.2007.01814.x – ident: bibr2-JIM.0000000000000230 doi: 10.1016/j.cgh.2008.11.005 – ident: bibr37-JIM.0000000000000230 doi: 10.2215/CJN.11291210 – ident: bibr8-JIM.0000000000000230 doi: 10.1681/ASN.V103594 – ident: bibr17-JIM.0000000000000230 doi: 10.1111/j.1572-0241.2007.01774.x – ident: bibr23-JIM.0000000000000230 doi: 10.1016/S0140-6736(01)07217-8 – ident: bibr38-JIM.0000000000000230 doi: 10.3109/00365520903443852 – ident: bibr18-JIM.0000000000000230 doi: 10.2337/dc06-9913 – ident: bibr35-JIM.0000000000000230 doi: 10.1042/cs1000161 – ident: bibr4-JIM.0000000000000230 doi: 10.1016/j.numecd.2010.10.003 – ident: bibr36-JIM.0000000000000230 doi: 10.1097/00005344-199904000-00020 – ident: bibr10-JIM.0000000000000230 doi: 10.1016/j.atherosclerosis.2009.10.034 – volume: 38 start-page: 1063 issue: 4 year: 2003 ident: bibr13-JIM.0000000000000230 publication-title: Hepatology contributor: fullname: Tsikas D – ident: bibr29-JIM.0000000000000230 doi: 10.1001/jama.287.11.1420 – ident: bibr34-JIM.0000000000000230 doi: 10.1161/01.CIR.99.24.3092 – ident: bibr9-JIM.0000000000000230 doi: 10.1177/1358863X10364552 – ident: bibr24-JIM.0000000000000230 doi: 10.1016/S0008-6363(03)00500-5 – ident: bibr12-JIM.0000000000000230 doi: 10.1177/0148607108321702 – ident: bibr5-JIM.0000000000000230 doi: 10.1097/00005344-199204002-00018 – ident: bibr31-JIM.0000000000000230 doi: 10.1016/j.ijcard.2006.11.058 – ident: bibr19-JIM.0000000000000230 doi: 10.1161/01.CIR.0000111245.75752.C6 – ident: bibr16-JIM.0000000000000230 doi: 10.1042/CS20030285 – ident: bibr25-JIM.0000000000000230 doi: 10.1007/s12020-012-9712-1 – ident: bibr33-JIM.0000000000000230 doi: 10.1016/S0735-1097(01)01318-3 – ident: bibr1-JIM.0000000000000230 doi: 10.1159/000336669 – ident: bibr21-JIM.0000000000000230 doi: 10.1016/0140-6736(92)90865-Z – ident: bibr15-JIM.0000000000000230 doi: 10.1210/jc.2006-2643 – ident: bibr20-JIM.0000000000000230 doi: 10.1002/hep.20701 – ident: bibr30-JIM.0000000000000230 doi: 10.1007/s00125-002-0975-6 – ident: bibr26-JIM.0000000000000230 doi: 10.1016/j.metabol.2010.07.027 – ident: bibr22-JIM.0000000000000230 doi: 10.1161/01.RES.0000181286.44222.61 |
SSID | ssj0026592 |
Score | 2.2017636 |
Snippet | Background and Aim
Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic... Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and... BACKGROUND AND AIMCardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic... |
SourceID | proquest crossref pubmed sage |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 871 |
SubjectTerms | Adult Arginine - analogs & derivatives Arginine - blood C-Reactive Protein - metabolism Case-Control Studies Female Humans Inflammation - pathology Insulin Resistance Liver - pathology Male Middle Aged Non-alcoholic Fatty Liver Disease - blood |
Title | Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation with Insulin Resistance, Inflammation, and Liver Histology |
URI | https://journals.sagepub.com/doi/full/10.1097/JIM.0000000000000230 https://www.ncbi.nlm.nih.gov/pubmed/26244718 https://search.proquest.com/docview/1716937590 |
Volume | 63 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZpCmMvY_dll6LBnta6iy-y5L1loyUpTShZC3kzki11oY0z6mSQ_pn9vv2LHVnyJU0Y6_JgglGOib_P8neOjs5B6EMqqGJEECcFOjmB6nIn8lLmSEJSHlHhuqqo9jkK-xfByYRMWq3fjayl5UIcJrdb95X8D6pwDnDVu2TvgWxlFE7Ad8AXjoAwHP8JY3i4dU45aMYzEMEzvn-qU4CK5IxevprNdLesBGY13SZ6BS7spe4GUVQJGWkBXjTHhQHHfAFS_FRnaOhqnNpiM0_OxGoHNml9LHMtOTMTfB9kCihltj-WiaDGUFF_pArZb8rfaV3g46fcXOK3Ad9v4CZUAeve9ZXp_dxf5nI1rfMH5lc5N8kG19P98fS2DjLw1Y1h_FB-n9m93jbG4ZIqW665uLY1jOmCpHEIMW2IDqU5R7vMAbeJNmd5O40aNtPGlM1MC5jq7U-3vlhMweKTwdAUvCw_nl1UWi_ZbX8Qbxu-g3Y9GhHaRrtfjkZn4yo6oNe3zW4Q84fKfZ4R_bTNzrqO2nCO1hITC610_hg9sijjnmHsE9SS2VP0YGgxfoZ-VcTFhrjYEBfPFa6Ji-8SF08z3CQuLoiLC75hS9zPuKQt1rTFlra4pu0BbpL2AANlrYmKss_RxfHR-de-YzuFOIkfRAsn5KmQPlUh-D9Cat3JlRsyFZBEcLiZnuQeYaErRKB8XyoZSpkINwgS4aWhkv4L1M7mmXyFsCLMTZiniGAsIF1fyCACn5pyNwQrzO8gp7zv8Q9TECYuEzkAp_guTh30vgQnhplbL8fxTM6XeVwUqvIpiWDMS4NaZdELQXaDbOygjxrG2E46-V8v9fo-g9-gh_WT9ha1FzdL-Q709ULsoR06oXuWn38AzqrNSw |
link.rule.ids | 315,786,790,27957,27958,31755,33780 |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+Plasma+Levels+of+Asymmetric+Dimethylarginine+in+Nonalcoholic+Fatty+Liver+Disease%3A+Relation+with+Insulin+Resistance%2C+Inflammation%2C+and+Liver+Histology&rft.jtitle=Journal+of+investigative+medicine&rft.au=Boga%2C+Salih&rft.au=Alkim%2C+Huseyin&rft.au=Koksal%2C+Ali+Riza&rft.au=Bayram%2C+Mehmet&rft.date=2015-10-01&rft.pub=SAGE+Publications&rft.issn=1081-5589&rft.eissn=1708-8267&rft.volume=63&rft.issue=7&rft.spage=871&rft.epage=877&rft_id=info:doi/10.1097%2FJIM.0000000000000230&rft.externalDocID=10.1097_JIM.0000000000000230 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1081-5589&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1081-5589&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1081-5589&client=summon |